<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0003003'>Colon cancer</z:hpo> predisposition is associated with mutations in BRCA1 </plain></SENT>
<SENT sid="1" pm="."><plain>BRCA1 protein stability depends on binding to BARD1 </plain></SENT>
<SENT sid="2" pm="."><plain>In different <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, expression of differentially spliced BARD1 isoforms is correlated with poor prognosis and decreased patient survival </plain></SENT>
<SENT sid="3" pm="."><plain>We therefore suspected a role of BARD1 isoforms in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We performed immunohistochemistry in 168 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, using four antibodies directed against differentially expressed regions of BARD1 </plain></SENT>
<SENT sid="5" pm="."><plain>We determined structure and relative expression of BARD1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> isoforms in 40 tumour and paired <z:mpath ids='MPATH_458'>normal</z:mpath> peri-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> tissues </plain></SENT>
<SENT sid="6" pm="."><plain>BARD1 expression was correlated with clinical outcome </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: BARD1 isoforms were expressed in 98% of cases and not correlated with BRCA1 </plain></SENT>
<SENT sid="8" pm="."><plain>BARD1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> isoforms were upregulated in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> as compared with paired <z:mpath ids='MPATH_458'>normal</z:mpath> peri-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> tissues </plain></SENT>
<SENT sid="9" pm="."><plain>Non-correlated expression and localisation of different <z:chebi fb="0" ids="53000">epitopes</z:chebi> suggested insignificant expression of full-length (FL) BARD1 </plain></SENT>
<SENT sid="10" pm="."><plain>Expression of N- and C-terminal <z:chebi fb="0" ids="53000">epitopes</z:chebi> correlated with increased survival, but expression of <z:chebi fb="0" ids="53000">epitopes</z:chebi> mapping to the middle of BARD1 correlated with decreased survival </plain></SENT>
<SENT sid="11" pm="."><plain>Middle <z:chebi fb="0" ids="53000">epitopes</z:chebi> are present in oncogenic BARD1 isoforms, which have pro-proliferative functions </plain></SENT>
<SENT sid="12" pm="."><plain>Correlated upregulation of only N- and C-terminal <z:chebi fb="0" ids="53000">epitopes</z:chebi> reflects the expression of isoforms BARD1δ and BARD1φ </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: Our results suggest that BARD1 isoforms, but not FL BARD1, are expressed in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> and affect its progression and clinical outcome </plain></SENT>
</text></document>